Skye Bioscience | BiotechTV

top of page

Aug 30

Skye Bioscience's CEO Punit Dhillon discusses next generation CB1 inhibition for obesity, and flags how key data from competitor Novo coming this quarter could impact the class

He describes Skye's CB1 program and the rationale for targeting fat tissue, and why today's versions of these therapies could be better...

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

Visit NYSE